Aclaris Therapeutics (ACRS) vs Assembly Biosciences (ASMB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Aclaris Therapeutics (ACRS) has outperformed Assembly Biosciences (ASMB) over the past year, gaining 84.8% versus a loss of 3.8%. Over five years, ASMB leads with a -41.3% price change compared with -79.8% for ACRS. Aclaris Therapeutics is the larger company by market cap ($522.6 million vs $449.6 million), about 1.2 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ACRS | ASMB |
|---|---|---|
| Share price | $3.55 | $22.08 |
| Market cap | $522.56M | $449.56M |
| 1-day change | +4.41% | -3.79% |
| YTD return | +12.96% | -32.52% |
| 1-year return | +84.78% | -3.81% |
| 5-year return | -79.77% | -41.33% |
| P/E ratio (TTM) | — | 21.23 |
| EPS (TTM) | $-0.58 | $1.04 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.60 | $39.71 |
| 52-week low | $1.74 | $21.80 |
| Distance from 52-week high | -46.21% | -44.40% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +186.76% | +135.51% |
| Average volume | 2.48M | 278.07K |
| Shares outstanding | 147.20M | 20.36M |
| Employees | 69 | 73 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- ACRS has outperformed ASMB by 88.6 percentage points over the past year.
About Aclaris Therapeutics
ACRS stock →Aclaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering and developing novel molecule product candidates for immuno-inflammatory diseases in the United States. The company product pipeline includes Bosakitug (ATI-045), an anti-thymic stromal lymphopoietin monoclonal antibody in Phase 2 trial to treat moderate to severe atopic dermatitis, asthma, chronic rhinosinusitis with nasal polyps, and moderate to severe chronic obstructive pulmonary disease; ATI-2138, an potent and selective novel investigational dual inhibitor of ITK and JAK3 in Phase 2a trial for the treatment for T cell-mediated autoimmune diseases; ATI-052, a humanized anti-TSLP and anti-IL4R bispecific antibody in Phase 1b to treat various atopic, immunologic, and respiratory diseases; ATI-9494, an oral, covalent, investigational dual inhibitor of ITK and Resting Lymphocyte Kinase (TXK), and other covalent JAK-sparing ITK inhibitors to treat modulate T cell biology across various diseases; and Lepzacitinib, a soft JAK 1/3 inhibitor for the treatment of atopic dermatitis and other dermatologic conditions.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
About Assembly Biosciences
ASMB stock →Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases worldwide. Its pipeline includes long-acting helicase-primase inhibitors candidates, including ABI-5366 and ABI-1179, which are in Phase 1 clinical studies for recurrent genital herpes; and ABI-6250, an orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical study for the treatment of chronic hepatitis delta virus (HDV) infection.
Health Care · Biotechnology: Pharmaceutical Preparations · 73 employees
ACRS vs ASMB FAQ
Which is bigger, Aclaris Therapeutics or Assembly Biosciences?
Aclaris Therapeutics (ACRS) is larger, with a market capitalization of $522.56M compared with $449.56M for Assembly Biosciences (ASMB).
Which stock has performed better over the past year, ACRS or ASMB?
ACRS returned +84.78% over the past 12 months, compared with -3.81% for ASMB (price return, excluding dividends). Past performance does not predict future results.
Are Aclaris Therapeutics and Assembly Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.